Building or investing in the CAR-T cell therapy market?

CAR-T is growing up. The leading products now make money and the first filing outside cancer is under way, but simpler drugs are competing for the same patients.

We've found a lot of interesting signals. For example, in May 2026, Kyverna began filing for FDA approval of its CAR-T for stiff person syndrome, which it says is the first filing for a CAR-T in an autoimmune disease. Then in August, Legend Biotech reported its first quarterly profit, as sales of Carvykti, the myeloma CAR-T it sells with J&J, grew about 50%. CAR-T is becoming a real business in blood cancers and is taking its first steps beyond cancer.

In this section, we look at why CAR-T is reaching more patients now, why autoimmune disease draws so much attention, and how T-cell engagers and CAR-T made inside the body could change the picture.

CAR-T can put some blood cancers into long remissions, yet many patients who could get it never do. The wait, the cost and the trip to a specialist center stop them first.

We look at six types of companies, from makers of approved autologous CAR-T and donor-made cells to multi-target and armored CARs, manufacturing platforms and delivery tools. Their buyers include cancer centers, insurers and the big drugmakers that license programs. For each, we rank the biggest pains, like weeks of manufacturing, failed batches, the chemotherapy patients need before infusion, and side effects that require a hospital stay.

This shows which problems hospitals and partners will pay to solve now, and which still need more patient data.

Most CAR-T revenue comes from a one-time price per patient, often several hundred thousand dollars. Around it, companies earn money from licensing deals, milestones, manufacturing services and capacity contracts.

We look at who pays and where the costs pile up. An autologous product needs a separate batch for every patient, so a failed run costs money and a factory slot. Donor-made cells could spread the cost over many patients, but they still have to show that their results last. Manufacturing platforms sell capacity or machines to drugmakers, and often depend on a few big contracts.

You'll see which models keep their margins as more patients are treated, and which ones rely on prices that hospitals and insurers may refuse to pay.

Behind our growth rate are specific reasons CAR-T could reach many more patients. We spell them out here.

Some drivers are clear: use in earlier lines of treatment, new approvals, and autoimmune diseases like lupus and myasthenia gravis. Others feed each other. Faster manufacturing means fewer patients get too sick while they wait. Treatment outside big hospitals widens the market. And each autoimmune result brings in more pharma money for the next trial.

Before building or investing, you should know what it takes to make CAR-T faster, cheaper and safe enough for clinics far from the top cancer centers.

Johnson & Johnson and Legend Biotech, the partners behind Carvykti, lead the sales charts, but CAR-T goes far beyond one myeloma drug.

Many smaller companies attack one step of the process. Some build closed, automated machines that make a batch with fewer staff. Others design CARs that can be switched off, hit two targets at once, or survive in solid tumors. A growing number in China take programs into patients quickly and license them to Western drugmakers.

They're hard to compare because results come from small trials, in different diseases, often measured in different ways. And many manufacturing players work behind a drugmaker's brand, so their name never appears on the product.

Below, you'll find the market grids and ecosystem maps we've built to show who makes which type of CAR-T, for which disease, and who builds the tools behind them.

Autolus Therapeutics, Cellares, Allogene Therapeutics… a few CAR-T companies are moving ahead, each with a different bet. Only one of them sells an approved therapy so far.

Autolus took its own CAR-T, Aucatzyl, to approval for adult leukemia in the US in 2024 and sells it itself, with sales more than doubling in a year. Cellares builds automated factories, has a $380M manufacturing deal with Bristol Myers Squibb, and raised $257M in January 2026 to open sites in the US, Europe and Japan. Allogene makes CAR-T from donor cells, ready within days, and passed an interim check in its main lymphoma trial in April 2026, though final results are still years away.

We'll look at how these teams chose where to compete, from selling a therapy to building the factory, and how they paid for it before the profits came.